Salix Pharmaceuticals, Ltd.
(Public, NASDAQ:SLXP) Watch this stockFind more results for
SLXP
Advertisement
Events
Dec 2, 2009
Piper Jaffray Healthcare Conference
- 1:00PM EST -
Nov 18, 2009
Analyst Meeting
Nov 11, 2009
Credit Suisse Healthcare Conference
Nov 9, 2009
Q3 2009 Earnings Conference Call -
Nov 9, 2009
Q3 2009 Earnings Release
Oct 5, 2009
JMP Securities Healthcare Focus Conference
Sep 9, 2009
Thomas Weisel Partners Healthcare Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -11.14% | -26.31% |
| Operating margin | -8.95% | -26.10% |
| EBITD margin | - | -18.83% |
| Return on average assets | -7.64% | -11.79% |
| Return on average equity | -12.30% | -17.31% |
| Employees | 280 | - |
Address
1700, Perimeter Park Drive
Morrisville, NC 27560
United States - Map
+1-919-8621000 (Phone)
+1-919-8621095 (Fax)
Morrisville, NC 27560
United States - Map
+1-919-8621000 (Phone)
+1-919-8621095 (Fax)
Website links
Company website:
http://www.salix.com
http://www.salix.com
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Salix Pharmaceuticals, Ltd. discussed on blogs
Ranking All U.S. Stocks by Weekly Performance - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 21, 2009
Salix Pharmaceuticals, Ltd. discussions
View all discussions »Description
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.
Officers and directors
| John F. Chappell | Chairman of the Board | |
| Carolyn J. Logan | President, Chief Executive Officer, Director | |
| Adam C. Derbyshire | Chief Financial Officer, Senior Vice President - Finance and Administration | |
| William P. Forbes | Vice President - Research and Development, Chief Development Officer | |
| Thomas W. D'Alonzo | Director | |
| Richard A. Franco Sr. | Director | |
| William P. Keane | Director | |
| Mark A. Sirgo | Director |